rAAV rh.74 Vascular Delivery of Alpha-Sarcoglycan
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for muscular dystrophies, including limb girdle muscular dystrophies such as LGMD2D, are inadequate, leading to progressive muscle weakness and limited quality of life, with a need for effective therapeutic options to prevent or delay disease progression.
Innovation Solution
The use of recombinant adeno-associated virus (rAAV) vectors, specifically AAV rh.74, for delivering an alpha-sarcoglycan gene expression cassette through vascular delivery methods like limb perfusion, targeting muscle cells to improve muscle function and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intramuscular injection of expression vector is used for gene replacement therapy, then alpha-sarcoglycan gene can be delivered to muscle cells, but treatment effectiveness is insufficient and disease progression continues
Solution Approach 1:
The patent changes the delivery parameters by using vascular perfusion instead of intramuscular injection, and by using rAAV rh.74 vector with specific genetic modifications (self-complementary genome, enhanced promoter) to improve gene delivery efficiency and treatment effectiveness
Solution Approach 2:
The patent introduces rAAV rh.74 as an intermediary vector that mediates gene delivery more effectively than previous methods, utilizing its specific capsid properties and self-complementary genome to enhance transduction efficiency of the alpha-sarcoglycan gene into muscle cells
2Quantity of substance
If conventional gene delivery methods are used, then some gene expression can be achieved, but muscle transduction efficiency is limited
Solution Approach 1:
The patent employs self-complementary AAV genome architecture and enhanced promoter elements to dramatically increase gene expression levels and muscle transduction efficiency compared to conventional single-stranded AAV vectors
Solution Approach 2:
The patent creates a composite gene delivery system combining rAAV rh.74 capsid with self-complementary genome and enhanced promoter elements to achieve superior transduction efficiency and sustained gene expression
Data Source
AI summary
The present invention relates to recombinant adeno-associated virus (rAAV) delivery of an alpha-sarcoglycan gene. The invention provides rAAV products and methods of using the rAAV in the treatment of limb girdle muscular dystrophies such as LGMD2D.